Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

201674 citationsJournal Articlehybrid Open Access

Authors

Angus Dalgleish · St George's, University of London

Justin Stebbing · Hammersmith Hospital

Douglas JA Adamson · Ninewells Hospital

Seema Safia Arif · Velindre Cancer Centre

Paolo Bidoli · Azienda Ospedaliera San Gerardo

David K. Chang · Royal Blackburn Teaching Hospital

Sue Cheeseman

Abstract

IMM-101 with GEM was as safe and well tolerated as GEM alone, and there was a suggestion of a beneficial effect on survival in patients with metastatic disease. This warrants further evaluation in an adequately powered confirmatory study.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Cancer Genomics and Diagnostics Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 115, Issue 7, pp. 789-796

DOI: 10.1038/bjc.2016.271

Field-Weighted Citation Impact: 4.89